A post-approval study of adalimumab for Crohn's disease, which was required by the FDA, did not result in any new safety signals, researchers said. Five-year study data presented at the ACG annual conference also showed improvements from baseline in all assessment categories after three months of treatment in new patients.

Full Story:
Doctor's Guide

Related Summaries